Valuation: ACLS THER

Market Cap 944M 808M 756M 692M 1.3B 90.28B 1.32B 8.93B 3.48B 45.35B 3.54B 3.47B 150B P/E 2026 *
-9.82x
P/E 2027 * -7.92x
Enterprise Value 790M 677M 634M 580M 1.09B 75.63B 1.1B 7.49B 2.92B 37.99B 2.97B 2.9B 126B EV / Sales 2026 *
126x
EV / Sales 2027 * 154x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.25%+8.36%+59.94%+196.82% 32.17B
Weighted average by Cap. +0.74%+9.48%+59.05%+157.80%

Financials

2026 *2027 *
Net sales 6.29M 5.39M 5.04M 4.61M 8.66M 602M 8.77M 59.53M 23.22M 302M 23.61M 23.09M 999M 5.18M 4.44M 4.15M 3.8M 7.13M 496M 7.23M 49.07M 19.13M 249M 19.46M 19.03M 824M
Net income -91.02M -77.97M -72.95M -66.78M -125M -8.71B -127M -862M -336M -4.37B -342M -334M -14.47B -114M -97.84M -91.55M -83.8M -157M -10.93B -159M -1.08B -422M -5.49B -429M -420M -18.16B
Net Debt -153M -131M -123M -112M -211M -14.65B -214M -1.45B -565M -7.36B -575M -562M -24.34B -147M -126M -117M -108M -202M -14.02B -204M -1.39B -541M -7.04B -550M -538M -23.3B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-